|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Poly (ethylenimine)-mediated transfection:a new paradigm for gene delivery显示文摘 | Barry MA Sadhu P | 2000 | JBiomed Mater Res2000，51，3： | 1 |
| 2 | Adjuvant paelitaxel and Trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 3 | A phase I trial of dasatinib,an SRC-family kinase inhibitor,in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer显示文摘 | Secord AA Teoh DK Barry WT | 2012 | Clin Cancer Res2012，18，19： | 1 |
| 4 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 5 | Poly(ethylenimine)-mediated transfection:a new paradigm for gene delivery 显示文摘 | Godbey WT Barry MA Saggau P | 2000 | J Biomed Mater Res2000，51，： | 1 |
| 6 | Poly (ethyleni mine)-mediated transfection: a new paradigm for gene delivery 显示文摘 | Godbey WT Barry MA Saggau P | 2000 | J Biomed Mater Res2000，51，32： | 1 |
| 7 | Poly (ethylenimine)-mediated transfection: a new paradigm for gene delivery显示文摘 | GODBEY WT BARRY MA SAGGAU P | 2000 | J Biomed Mater Res2000，51，： | 1 |
| 8 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 9 | Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 10 | Adjuvant paclitaxel and trastuzumab for node-negative, HER-2 positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N EnglJ Med2015，372，2： | 1 |
| 11 | Poly(ethylenimine)mediated transfection: a new paradigm for gene delivery 显示文摘 | Godbey WT Barry MA Saggau P | 2000 | J Biomed Mater Res2000，51，3： | 1 |
| 12 | Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study显示文摘 | Liu JF Barry WT Birrer M | 2014 | Lancet Oncol2014，15，1： | 1 |
| 13 | A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplafin in patients with advanced or recurrent ovarian cancer 显示文摘 | SECORD A A TEOH D K BARRY WT | 2012 | Clin Cancer Res2012，18，19： | 1 |
| 14 | dasatinib, an SRC-family kinase inhibitor, paclitaxel and carboplatin in patients with ovarian cancer 显示文摘 | Secord AA Teoh D K Barry WT | 2012 | Clin Cancer Res2012，18，19： | 1 |
| 15 | Significance analysis of functional categories in gene expression studies: a structured permutation approach 显示文摘 | Barry WT Nobel AB Wright FA | 2005 | Bioinformatics2005，21，： | 1 |
| 16 | Polyarylacetylene-matrix composites for solid rocket motor components显示文摘 | Katzman HA Mallon JJ Barry WT | 1995 | Journal of Advanced Materials1995，26，3： | 1 |
| 17 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 18 | Significance analysis of functional categories in gene expression 'studies: a structured permutation approach显示文摘 | Barry WT AB Nobel FA Wright | 2005 | Bioinformatics2005，21，9： | 1 |
| 19 | Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 20 | Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein显示文摘 | Burns KE Liu WT Boshoff HI Dorrestein PC Barry CE 3rd | 2009 | J Biol Chem2009，284，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员